1887

Abstract

Restricted replication in the respiratory tract of rhesus monkeys is an intrinsic property of bovine parainfluenza virus type 3 (bPIV-3) strains. This host range phenotype of bPIV-3 has been utilized as a marker to evaluate the attenuation of bPIV-3 vaccines for human use. Two safety, immunogenicity and efficacy studies in primates evaluated and compared three human parainfluenza virus type 3 (hPIV-3) vaccine candidates: biologically derived bPIV-3, a plasmid-derived bPIV-3 (r-bPIV-3) and a chimeric bovine/human PIV-3 (b/hPIV-3). These studies also examined the feasibility of substituting Vero cells, cultured in the presence or absence of foetal bovine serum, for foetal rhesus lung-2 (FRhL-2) cells as the tissue culture substrate for the production of bPIV-3 vaccine. The results demonstrated that (i) Vero cell-produced bPIV-3 was as attenuated, immunogenic and efficacious as bPIV-3 vaccine grown in FRhL-2 cells, (ii) plasmid-derived bPIV-3 was as attenuated, immunogenic and efficacious as the biologically derived bPIV-3 and (iii) the b/hPIV-3 chimera displayed an intermediate attenuation phenotype and protected animals completely from hPIV-3 challenge. These results support the use of bPIV-3 vaccines propagated in Vero cells in human clinical trials and the use of b/hPIV-3 as a virus vaccine vector to express foreign viral antigens.

Loading

Article metrics loading...

/content/journal/jgv/10.1099/vir.0.19522-0
2003-12-01
2019-12-08
Loading full text...

Full text loading...

/deliver/fulltext/jgv/84/12/vir843253.html?itemId=/content/journal/jgv/10.1099/vir.0.19522-0&mimeType=html&fmt=ahah

References

  1. Bailley, J. E., McAuliffe, J. M., Skiadopoulos, M. H., Collins, P. L. & Murphy, B. R. ( 2000; ). Sequence determination and molecular analysis of two strains of bovine parainfluenza virus type 3 that are attenuated for primates. Virus Genes 20, 173–182.[CrossRef]
    [Google Scholar]
  2. Coelingh, K. J., Winter, C. C., Murphy, B. R., Rice, J. M., Kimball, P. C., Olmsted, R. A. & Collins, P. L. ( 1986; ). Conserved epitopes on the hemagglutinin–neuraminidase proteins of human and bovine parainfluenza type 3 viruses: nucleotide sequence analysis of variants selected with monoclonal antibodies. J Virol 60, 90–96.
    [Google Scholar]
  3. Greenberg, D. P., Yeh, S., Yogev, R. & 7 other authors ( 1999; ). Evaluation of the safety, immunogenicity, and virus shedding of an intranasal live attenuated bovine parainfluenza virus type 3 vaccine in infants. Annual Meeting of the Pediatric Academic Societies (San Francisco, USA, 1–4 May 1999). Abstract #942.
  4. Haller, A. A., Miller, T., Mitiku, M. & Coelingh, K. L. ( 2000; ). Expression of the surface glycoproteins of human parainfluenza virus type 3 by bovine parainfluenza virus type 3, a novel attenuated virus vaccine vector. J Virol 74, 11626–11635.[CrossRef]
    [Google Scholar]
  5. Haller, A. A., MacPhail, M., Mitiku, M. & Tang, R. S. ( 2001; ). A single amino acid substitution in the viral polymerase creates a temperature-sensitive and attenuated recombinant bovine parainfluenza virus type 3. Virology 288, 342–350.[CrossRef]
    [Google Scholar]
  6. Hsuing, G. D. ( 1982; ). Diagnostic Virology, 3rd edn, p. 143. Princeton, NJ: Yale University Press.
  7. Karron, R. A., Wright, P. F., Hall, S. L. & 7 other authors ( 1995; ). A live attenuated bovine parainfluenza virus type 3 vaccine is safe, infectious, immunogenic, and phenotypically stable in infants and children. J Infect Dis 171, 1107–1114.[CrossRef]
    [Google Scholar]
  8. Karron, R. A., Makhene, M., Gay, K., Wilson, M. H., Clements, M. L. & Murphy, B. R. ( 1996; ). Evaluation of a live attenuated bovine parainfluenza type 3 vaccine in two- to six-month-old infants. Pediatr Infect Dis J 15, 650–654.[CrossRef]
    [Google Scholar]
  9. Klippmark, E., Rydbeck, R., Shibuta, H. & Norrby, E. ( 1990; ). Antigenic variation of human and bovine parainfluenza virus type 3 strains. J Gen Virol 71, 1577–1580.[CrossRef]
    [Google Scholar]
  10. Lee, M. S., Greenberg, D. P., Yeh, S. H. & 12 other authors ( 2001; ). Antibody responses to bovine parainfluenza virus type 3 (PIV3) vaccination and human PIV3 infection in young infants. J Infect Dis 184, 909–913.[CrossRef]
    [Google Scholar]
  11. Reed, L. J. & Muench, H. ( 1938; ). A simple method for estimating fifty percent end points. Am J Hyg 27, 493–497.
    [Google Scholar]
  12. Schmidt, A. C., McAuliffe, J. M., Huang, A., Surman, S. R., Bailly, J. E., Elkins, W. R., Collins, P. L., Murphy, B. R. & Skiadopoulos, M. H. ( 2000; ). Bovine parainfluenza virus type 3 (BPIV3) fusion and hemagglutinin–neuraminidase glycoproteins make an important contribution to the restricted replication of BPIV3 in primates. J Virol 74, 8922–8929.[CrossRef]
    [Google Scholar]
  13. van Wyke Coelingh, K. L., Winter, C. C., Tierney, E. L., London, W. T. & Murphy, B. R. ( 1988; ). Attenuation of bovine parainfluenza virus type 3 in nonhuman primates and its ability to confer immunity to human parainfluenza virus type 3 challenge. J Infect Dis 157, 655–662.[CrossRef]
    [Google Scholar]
  14. Welliver, R. C., Wong, D. T., Sun, M. & McCarthy, N. ( 1986; ). Parainfluenza virus bronchiolitis. Epidemiology and pathogenesis. Am J Dis Child 140, 34–40.[CrossRef]
    [Google Scholar]
http://instance.metastore.ingenta.com/content/journal/jgv/10.1099/vir.0.19522-0
Loading
/content/journal/jgv/10.1099/vir.0.19522-0
Loading

Data & Media loading...

Most Cited This Month

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error